Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management.

Authors

Shuchita Gupta, Einstein Institute for Heart and Vascular HealthFollow
Vincent M. Figueredo, M.D., Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

3-1-2014

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in International Journal of Cardiology, Volume 172, Issue 1, March 2014, Pages 40-46.

The published version is available at DOI: 10.1016/j.ijcard.2013.12.180. Copyright © Elsevier Inc.

Abstract

Tachycardia mediated cardiomyopathy (TMC) is a reversible form of dilated cardiomyopathy that can occur with most supraventricular and ventricular arrhythmias. Despite the plethora of literature describing this entity in animal models, as well as humans, it remains poorly understood. Over the last decade, new etiologies of TMC, such as frequent premature ventricular complexes in normal hearts, have been identified. Recent advances in catheter-based ablation therapies, particularly for atrial fibrillation and ventricular arrhythmias, have added a new dimension to the treatment of this condition. This review describes the pathophysiology, proposed mechanisms, clinical features and management in various arrhythmic conditions.

Recommended Citation

Gupta, Shuchita and Figueredo, M.D., Vincent M., "Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management." (2014). Division of Cardiology Faculty Papers. Paper 49.
https://jdc.jefferson.edu/cardiologyfp/49

PubMed ID

24447747